Tuesday, August 21, 2018
Tags Bristol-Myers Squibb

Tag: Bristol-Myers Squibb

Study Preserves Hopes for Roche’s Tecentriq in Lung Cancer

By John Miller ZURICH (Reuters)  Swiss drugmaker Roche's hopes of having the first immunotherapy cocktail to be approved as an initial treatment for an aggressive form...

Mixed Results for Bristol/Nektar Combination in Cancer Trial

Chicago (Reuters) Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led...

Roche Drugs Show Limited Benefit in Lung, Breast Cancer Trials

By Deena Beasley CHICAGO (Reuters)  In a disappointment for Roche Holding AG, two of its oncology drugs provided only modest protection from disease progression in lung...

Roche’s Tecentriq Cocktail Adds to Lung Cancer Survival Success

ZURICH (Reuters) Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks...

Roche’s Tecentriq Notches Third Cancer Cocktail Trial Win

By John Miller ZURICH (Reuters) Roche's immunotherapy Tecentriq on Tuesday racked up a third trial win in combination with other cancer drugs, a boost for...

Big Pharma, Big Data: Why Drugmakers Want Your Health Records

By Ben Hirschler LONDON (Reuters) Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start...
banner